Despite the lack of solid evidence of TNF implication in the pathogenesis of AOSD as opposed to rheumatoid arthritis, anti-TNF agents have been used in AOSD refractory cases with modest success, particularly in the chronic articular form of the disease lagging in efficacy behind IL-1 and IL-6 inhibitors. This evidence concerns the gene IL6 and adult-onset Still disease.